{"preliminary_commentary":{"by_channel":{"x_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"name":"SWOG S2209","nct_id":"NCT05561387","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=swog-s2209-nct05561387. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"INDUCTION CYCLES 1-9: Patients receive bortezomib SC on days 1, 8, 15, and 22 of each cycle, lenalidomide PO on days 1-21 of each cycle, and dexamethasone PO on days 1, 8, 15, and 22 of each cycle. Treatment repeats every 28 days for up to 9 cycles in the absence of disease progression or unacceptable toxicity.\n\nMAINTENANCE CYCLES 10+: Patients receive lenalidomide PO on days 1-21 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.","label":"Arm I (VRd-Lite)","type":"ACTIVE_COMPARATOR"},{"description":"INDUCTION CYCLES 1-9: Patients receive daratumumab and hyaluronidase-fihj SC on days 1, 8, 15, and 22 of cycles 1-2, days 1 and 15 of cycles 3-6, and day 1 of cycles 7-9, lenalidomide PO on days 1-21 of each cycle, and dexamethasone PO on days 1, 8, 15, and 22 of each cycle. Treatment repeats every 28 days for up to 9 cycles in the absence of disease progression or unacceptable toxicity.\n\nMAINTENANCE CYCLES 10+: Patients receive lenalidomide PO on days 1-21 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.","label":"Arm II (DRd-R)","type":"EXPERIMENTAL"},{"description":"INDUCTION CYCLES 1-9: Patients receive daratumumab and hyaluronidase-fihj SC on days 1, 8, 15, and 22 of cycles 1-2, days 1 and 15 of cycles 3-6, and day 1 of cycles 7-9, lenalidomide PO on days 1-21 of each cycle, and dexamethasone PO on days 1, 8, 15, and 22 of each cycle. Treatment repeats every 28 days for up to 9 cycles in the absence of disease progression or unacceptable toxicity.\n\nMAINTENANCE CYCLES 10+: Patients receive daratumumab and hyaluronidase-fihj SC on day 1 of each cycle and lenalidomide PO on days 1-21 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.","label":"Arm III (DRd-DR):","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2031-05-30","type":"ESTIMATED"},"conditions":["Plasma Cell Myeloma"],"enrollment":{"count":510,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Bortezomib","otherNames":["[(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid","LDP 341","MLN341","PS-341","PS341","Velcade"],"type":"DRUG"},{"name":"Daratumumab and Hyaluronidase-fihj","otherNames":["DARA Co-formulated with rHuPH20","DARA/rHuPH20","Daratumumab + rHuPH20","Daratumumab with rHuPH20","Daratumumab-rHuPH20","Daratumumab/Hyaluronidase-fihj","Daratumumab/rHuPH20 Co-formulation","Darzalex Faspro","Darzalex/rHuPH20","HuMax-CD38-rHuPH20","Recombinant Human Hyaluronidase Mixed with Daratumumab"],"type":"DRUG"},{"name":"Dexamethasone","otherNames":["Aacidexam","Adexone","Aknichthol Dexa","Alba-Dex","Alin","Alin Depot","Alin Oftalmico","Amplidermis","Anemul mono","Auricularum","Auxiloson","Baycadron","Baycuten","Baycuten N","Cortidexason","Cortisumman","Decacort","Decadrol","Decadron","Decadron DP","Decalix","Decameth","Decasone R.p.","Dectancyl","Dekacort","Deltafluorene","Deronil","Desamethasone","Desameton","Dexa-Mamallet","Dexa-Rhinosan","Dexa-Scheroson","Dexa-sine","Dexacortal","Dexacortin","Dexafarma","Dexafluorene","Dexalocal","Dexamecortin","Dexameth","Dexamethasone Intensol","Dexamethasonum","Dexamonozon","Dexapos","Dexinoral","Dexone","Dinormon","Dxevo","Fluorodelta","Fortecortin","Gammacorten","Hemady","Hexadecadrol","Hexadrol","Lokalison-F","Loverine","Methylfluorprednisolone","Millicorten","Mymethasone","Orgadrone","Spersadex","TaperDex","Visumetazone","ZoDex"],"type":"DRUG"},{"name":"Lenalidomide","otherNames":["CC-5013","CC5013","CDC 501","Revlimid"],"type":"DRUG"},{"name":"Quality-of-Life Assessment","otherNames":["Quality of Life Assessment"],"type":"OTHER"},{"name":"Questionnaire Administration","otherNames":[],"type":"OTHER"}],"last_update":"2026-06-10","lead_sponsor":"SWOG Cancer Research Network","official_title":"A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of \"Intermediate Fit\" Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single-Agent Maintenance","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2031-05-30","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression free survival (PFS) of Arm 1 versus (vs.) Arm 2","timeFrame":"From date of randomization to date of first documentation of progression or symptomatic deterioration, or death due to any cause, or assessed up to 10 years"},{"measure":"Overall survival (OS) of Arm 1 vs. Arm 3","timeFrame":"From date of randomization to date of death due to any cause, or assessed up to 10 years"}],"references":[],"start_date":{"date":"2023-10-12","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment","url":"https://clinicaltrials.gov/study/NCT05561387"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/swog-s2209-nct05561387"}